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Aims: To determine if clotting, platelet, and endothelial function were affected by simu-
lated short-haul commercial air flight conditions (SF) in participants with type 2 diabetes 
(T2DM) compared to controls.
Methods: 10 participants with T2DM (7 females, 3 males) and 10 controls (3 females, 
7 males) completed the study. Participants were randomized to either spend 2 h in an 
environmental chamber at sea level conditions (temperature: 23°C, oxygen concentra-
tion 21%, humidity 45%), or subject to a simulated 2-h simulated flight (SF: temperature: 
23°C, oxygen concentration 15%, humidity 15%), and crossed over 7 days later. Main 
outcome measures: clot formation and clot lysis parameters, functional platelet activa-
tion markers, and endothelial function measured by reactive hyperemia index (RHI) by 
EndoPAT and serum microparticles.
Results: Comparing baseline with SF conditions, clot maximal absorption was increased 
in controls (0.375  ±  0.05 vs. 0.39  ±  0.05, p  <  0.05) and participants with T2DM 
(0.378 ± 0.089 vs. 0.397 ± 0.089, p < 0.01), while increased basal platelet activation 
for both fibrinogen binding and P-selectin expression (p < 0.05) was seen in participants 
with T2DM. Parameters of clot formation and clot lysis, stimulated platelet function 
(stimulated platelet response to ADP and sensitivity to prostacyclin), and endothelial 
function were unchanged.
Conclusion: While SF resulted in the potential of denser clot formation with enhanced 
basal platelet activation in T2DM, the dynamic clotting, platelet, and endothelial markers 
were not affected, suggesting that short-haul commercial flying adds no additional 
hazard for venous thromboembolism for participants with T2DM compared to controls.
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INTRODUCTION
The environmental conditions on an aircraft result in reduced 
barometric pressure with a concomitant decrease in the partial 
pressure of oxygen resulting in lowering of the gas exchange in 
the lungs causing hypoxia. Aircraft cabins are pressurized to 
maintain good oxygenation, and the cabin altitude is around 
8,000 ft (2,438 m). The humidity is kept low at 10–20% com-
pared to 40–50% seen in an average building at sea level (1). 
The conditions inside an aircraft are irrespective of the flying 
altitude. Air travel was shown to increase the risk to develop 
venous thromboembolism (VTE) when risk factors are present 
(2), and traveler’s thrombosis is defined as a VTE occurring 
within 4 weeks after long-haul travel or occurring during the 
travel: the term “air-travel thrombosis” is used when the main 
part of the travel is air travel (3). Passengers have a medium 
risk to develop traveler’s DVT if they have two or more risk 
factors that include pregnancy or post-partum period, age over 
60 years, documented thrombophilia, a family history of VTE, 
large varicose veins and/or chronic venous insufficiency, use 
of the oral contraceptive pill (OCP) or hormone replacement 
therapy (HRT), body mass index over 30. Thrombophilia or 
OCP use increases the risk to 14- to 16-fold (4). The presence of 
risk factors such as previous VTE, manifest malignant disease 
or other severe illness, immobilization or recent major surgery 
represents a high risk to develop traveler’s DVT. In passengers 
without the above risk factors, a prolonged journey slightly but 
indeterminately increases the risk of VTE (3). There is no evi-
dence suggesting an association between hydration status and 
the development of VTE (5).
Evidence suggests that not only air travel, but any long-distance 
travel increases the risk of VTE development (6); however, when 
additional risk factors are present, the risk is increased with air 
travel (7). A case–control study estimated the risk of fatal pul-
monary embolism following a flight of at least 3 h’ duration was 
between 0.5 and 0.6 per million passengers (8). In a hypobaric 
hypoxia study involving 20 healthy male volunteers, the authors 
showed that prothrombin 1 and 2 fragment levels reached a maxi-
mum level at 2 h into exposure (9). The evidence that participants 
with diabetes may be more likely to develop a VTE than healthy 
individuals is supported in some studies (10, 11), but not others 
(12). The development of a VTE may be contributed to in type 2 
diabetes (T2DM) through a more compact clot structure through 
a smaller pore size and increased fiber thickness with more branch 
points (13), compared to on diabetes patients.
During blood clot formation, one of the most important steps 
is platelet activation that is known to be impaired in participants 
with T2DM. Platelet function abnormalities such as hypersen-
sitivity of platelets to aggregant factors and hyposensitivity to 
anti-aggregants are present in participants with T2DM contribut-
ing toward increased platelet activity at locations of endothelial 
damage (14, 15).
Hypoxia can affect the endothelium and blood clot formation 
that can increase the risk for thrombosis. Endothelial micropar-
ticles (EMPs) are vesicles shed by the endothelial cells (EC) and 
consist of cell membrane, cytoplasmic, and nuclear elements. 
EMPs express surface markers reflecting their cell of origin (16). 
Under normal physiological conditions microparticles (MPs) are 
constantly shed into the circulation of healthy individuals (17). 
However, the level of EMPs is elevated in the circulation after 
damage, activation, or apoptosis of the EC, such as that seen for 
acute coronary syndromes and diabetes (18), and in vivo correlate 
with T2DM complications (19).
Short haul travel has not been investigated and specific studies 
exploring the risk for patients with diabetes to develop travel-
related VTE are lacking. Given that hypobaric hypoxia showed 
prothrombotic changes at 2 h into exposure (9), this pilot study 
aimed to determine whether a simulated flight (SF) of 2 h duration 
in a hypoxic environment caused impairment in clotting indices, 
platelet function, and endothelial function, and whether this 
impairment was greater in participants with T2DM compared to 
healthy participants.
MATERIALS AND METHODS
All participants signed an informed consent form prior to their 
inclusion in the study.
Patients with T2DM were eligible for participation if they 
had a diagnosis of T2DM based on the WHO guidelines, they 
were on stable medication for diabetes during and for 3 months 
prior to the study (metformin being the only treatment per-
mitted), age between 45 and 75 years at the beginning of the 
study, women postmenopausal and not on HRT, no hypo- 
hyperglycemia requiring medical attention or diabetes-related 
hospitalization in the preceding 12 months. Healthy volunteers 
were eligible for participation if aged 45–75 at the start of the 
study and women being postmenopausal and not on HRT. 
Exclusion criteria for both groups included the presence of 
any medical condition or concurrent medication that would 
interfere with the results of the study (i.e., antiplatelet medica-
tion or anticoagulants, previous VTE), any major clinical event 
in the preceding 3 months, participants not wishing to disclose 
their participation to their registered General Practitioner, 
HbA1c > 9%, smokers, claustrophobia, or panic attacks, sub-
jects traveling by airplane or prolonged travel during the study 
or in the previous 4 weeks.
Twenty seven participants were screened for this study. Six 
participants failed screening or withdrew from the study (medi-
cation that affect platelet function [cyclooxygenase-2 inhibitor, 
n = 1; aspirin, n = 1], acute phase reaction at screening [n = 1], 
angina [n = 1], chronic obstructive pulmonary disease [n = 1] 
time commitments [n = 1]). One patient finished her participa-
tion in the study early due to intolerance of the chamber condi-
tions. Twenty participants completed the study. Ten with T2DM 
and 10 healthy controls (Table 1).
The study was approved by the Humber Bridge Regional Ethics 
Committee (12/YH/0016) and all participants provided written 
informed consent. The conduct of the trial was in accordance 
with ICH GCP and the Declaration of Helsinki.
Participants participated in two visits in the environmental 
chamber between April 2013 and December 2013. Following the 
screening visit, participants attended the environmental chamber 
(Design and Manufacture of Environmental Test Chambers, 
A3897 – SSR60-20H) on two separate occasions at the University 
TABLE 1 | Baseline patient characteristics.
Controls Type 2 diabetes Significance
N 10 10
Gender (male, female) 7/3 3/7
Age (years) 57.30 ± 10.48 66 ± 7.30 0.07
HbA1c (mmol/mol) (%) 34.20 ± 3.08
5.3 ± 0.5
41.70 ± 6.38
6.0 ± 1.0
0.05*
Weight (kg) 73.64 ± 11.57 91.08 ± 15.14 0.01*
BMI (kg/m2) 27.34 ± 3.88 31.34 ± 5.17 0.07
Waist/hip ratio 0.87 ± 0.08 0.94 ± 0.09 0.15
Data are expressed as mean ± SD.
BMI, body mass index.
*Significant difference.
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of Hull and were subject to one of two environmental conditions 
in random order, and then crossed over to the other environ-
mental condition 7 days later. One environmental condition was 
the control day, when participants were asked to spend 2 h in 
the environmental chamber at sea level conditions (temperature: 
23oC, oxygen concentration 21%, humidity 45%). The second 
environmental condition was when participants were asked to 
spend 2 h in the environmental chamber in hypoxic conditions, 
similar to a commercial flight air cabin conditions (temperature: 
23oC, oxygen concentration 15%, humidity 15%). Baseline and 2 h 
measurements were taken for each of the measured parameters.
Participants were investigated individually in the chamber 
and were seated throughout the visits and the same chairs used 
throughout the study. Participants were asked to refrain from 
walking during the study and they were allowed to consume 
water.
Samples for clotting experiments were spun at 3,500  g for 
15  min immediately after venepuncture, and then frozen at 
−80°C until batch analysis at the end of the study. Blood was 
prepared for platelet function and microparticles analysis within 
10 min. Participants arrived fasting to eliminate the postprandial 
effects and were provided lunch after the end of the visits in the 
environmental chamber.
Fibrin formation and clot structure analysis was undertaken 
using turbidimetric assays (20). Initial fibrin formation occurs 
during the “lag” phase, when half-staggered, double-stranded 
protofibrils are formed (21), and is equivalent to the clotting 
time. Maximum absorbance is the maximum optical density of 
the clot, and this is a measure of fibrin network density and fiber 
thickness. Lysis time is the time from full blood clot formation to 
50% lysis that is an indicator of fibrinolytic potential: lysis area 
is measured as area under the curve. This is a complex measure 
of clot formation time, clot density, and lysis potential. Higher 
maximum absorbance, longer lysis time, and larger lysis area are 
associated with increased cardiovascular risk (22, 23).
Platelets were identified by the pan-platelet marker CD42b 
from whole blood, and their function was determined by 
flow cytometry (FACSAria II, BD Biosciences). Samples 
were labeled with antibodies specifically against the exposed 
fibrinogen-binding surface receptor to assess activation, 
and samples were labeled with P-selectin (an antigen of the 
α-granules) to assess degranulation. These samples were then 
assessed in the presence of different concentrations of ADP 
that is an agonist of platelet activation but causes minimal 
degranulation. Activated platelet inactivation by prostacyclin 
(PG12) was also undertaken (24).
Endothelial microparticles were characterized by CD106 (with 
surface VCAM-1 expressed) and CD144 (surface VE-Cadherin 
expressed) positivity on flow cytometry (BD FACSCalibur). 
Microparticles were further characterized by their ability to bind 
annexin V on their surface. Total MPs were calculated using the 
following formula:
 
Total microparticles MPs were derived from MPsannexin V posi( ) tive
annexin V negativeMPs± .  
All antibodies were supplied by BD Biosciences and Thermo 
Fischer Scientific. AccuCheck counting beads supplied by 
Thermo Fischer Scientific.
Endothelial function was assessed using PAT arterial tonom-
etry using the EndoPAT 2000 (Itamar Madical Ltd., Israel) that 
is a reactive hyperemia-based, operator independent device 
(25, 26). Briefly, 2 disposable, inflatable probes were placed on 
the index fingers in a sitting position while resting. After 10 min 
of baseline signal registration, a BP cuff was inflated for 3 min 
and after release the test was continued for a further 5 min. The 
EndoPAT 2000 has been validated to assess endothelial function. 
A RHI lower than a cut-off value of 1.67 has 82% sensitivity and 
77% specificity to diagnose coronary endothelial dysfunction 
(27) and reproducibility is good with an interclass correlation 
of 0.74.
Statistical Analysis
Results are expressed as mean  ±  SD or median (25th, 75th 
centiles) where applicable. Differences between baseline and 
corresponding 2-h data were assessed using Student’s paired 
t-test for variables that showed normal distribution, or Wilcoxon 
signed rank test for variables that violated from the Gaussian 
distribution. Between group differences were calculated using 
unpaired t-test where the data showed normal distribution, or 
Mann–Whitney U-test where the distribution violated from 
the Gaussian distribution. Normality testing was performed 
using the Shapiro–Wilk test. Correlation was calculated using 
Pearson’s correlation test. Statistical analysis was performed 
using SPSS 19.0.0 (IBM Corp., New York, NY, USA) and 
statistical significance was defined as (p < 0.05). As this was a 
pilot study, no power analysis was applicable; however, power 
and sample size for pilot studies have been reviewed by Birkett 
and Day (28) who concluded that a minimum of 20 degrees-
of-freedom was required to estimate effect size and variability, 
hence, we recruited 10 participants per group.
RESULTS
Patient baseline characteristics are shown in Table  1 with 
participants with T2DM having a mean disease duration of 
5.75 ± 3.58 years. There was a significant difference in weight 
between healthy controls and patients with diabetes; however, 
BMI did not differ significantly.
TABLE 3 | Platelet activation and response to ADP prior to and after the relative hypoxia of the simulated flight (SF) intervention.
Fibrinogen binding
Controls Type 2 diabetes (T2DM)
Before After p CI Before After p CI
Basal 2.03 ± 0.50 2.39 ± 1.12 0.30 −1.10 to 0.38 1.56 ± 0.45 2.17 ± 0.50 0.05* −1.21 to 0.01
ADP 0.1 µm 5.04 ± 2.63 4.70 ± 2.08 0.62 −1.18 to 1.86 5.23 ± 3.27 5.42 ± 2.83 0.90 −3.32 to 2.95
ADP 1 µm 45.50 ± 16.42 46.62 ± 11.92 0.63 −6.14 to 3.91 49.14 ± 14.39 47.28 ± 13.26 0.79 −14.07 to 17.81
ADP 10 µm 63.17 ± 12.89 67.52 ± 10.25 0.09 −9.52 to 0.83 68.84 ± 14.19 55.03 ± 9.86 0.60 −11.21 to 18.09
P-selectin expression
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
Basal 2.18 (1.65, 5.58) 2.08 (1.31, 5.60) 0.50 −0.59 (5) 2.35 (1.80, 6.55) 6.20 (3.28, 7.08) 0.05* −1.96 (2)
ADP 0.1 µm 6.61 ± 3.97 5.60 ± 3.28 0.40 −1.56 to 3.58 8.41 ± 4.56 9.53 ± 3.60 0.56 −5.42 to 3.17
ADP 1 µm 48.43 ± 19.61 47.99 ± 15.62 0.91 −7.80 to 8.67 54.57 ± 14.14 55.03 ± 9.86 0.94 −14.69 to 13.77
ADP 10 µm 67.58 ± 18.04 70.68 ± 13.60 0.26 −8.96 to 2.75 73.89 ± 12.20 77.42 ± 9.26 0.52 −15.73 to 8.68
Base line platelet activation following the SF was seen for participants with T2DM that was not exacerbated by ADP stimulated platelet activation. This suggests that whilst the 
diabetes platelet may be more prone to being activated by the SF, the activated response does not differ to normal.
*Significant difference.
TABLE 2 | Clotting indices in healthy volunteers and participants with type 2 diabetes (T2DM) before and after simulated flight (SF) and exposed to oxygen 
concentration 15% and humidity 15%.
Hypoxia
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
Lag time 455.00 ± 52.99 424.40 ± 63.02 0.17 −16.35 to 77.55 446.90 ± 93.57 450.50 ± 61.02 0.89 −58.39 to 51.19
Maximum absorption 0.375 ± 0.050 0.390 ± 0.053 0.04* −0.32 to 0.01 0.378 ± 0.076 0.397 ± 0.089 0.01* −0.03 to 0.01
Lysis time 1500.33  
(1261.25, 1822.92)
1570.83  
(1386.92, 1868.00)
0.17 –1.38 (4) 1422.33  
(1330.00, 1458.42)
1362.67  
(1276.17, 1507.42)
0.29 −1.07 (7)
Lysis area 658.20 ± 289.27 675.11 ± 215.61 0.64 −95.23 to 61.40 556.05 ± 157.71 591.34 ± 219.85 0.29 −106.53 to 35.94
Maximal absorption indicating clot density was increased in both normal and T2DM participants, though other functional clot elements were unchanged following the SF.
*Significant difference.
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Maximal absorption indicating clot density was increased in 
both normal and participants with T2DM (p = 0.04, p < 0.01) 
following the SF (Table 2), but did not differ on the control day. 
There was no difference in baseline clotting parameters between 
healthy controls and participants with T2DM (data not shown). 
Lag time, that is equivalent to the clotting time, did not differ 
following the SF (Table 2), while it significantly decreased during 
the control day. Lysis time and lysis area did not differ at baseline 
between groups, on the control day and following the SF (Table 2).
There was an increase in platelet activation for both fibrinogen 
and p-selectin following the SF though platelet response to ADP 
(Table 3) and sensitivity to PGI2 was unchanged (Table 4). There 
was no difference in baseline platelet function between controls 
and participants with T2DM nor on the control day (data not 
shown).
Annexin V negative and total VCAM-1 positive MPs were 
significantly higher in participants with T2DM compared to 
controls (248 ± 130 vs. 144 ± 68, p = 0.04; 314 ± 130 vs. 196 ± 65, 
p = 0.02, respectively) indicating impaired baseline endothelial 
function in participants with T2DM compared to the controls. 
However, there was no increase in MP counts during the SF, and 
the RHI also remained unchanged following the SF. Neither of 
these parameters changed during the control experiment (data 
not shown).
Results from the control day are presented in Tables 5 and 6.
DISCUSSION
This is the first study to assess the physiological changes that 
might affect thrombus formation when simulating a short dura-
tion commercial air flight, comparing participants with T2DM 
and healthy controls. Short-haul travel is very common and has 
not been investigated, and specific studies exploring the risk for 
patients with diabetes to develop travel-related VTE are lacking. 
Given that hypobaric hypoxia showed prothrombotic changes at 
2 h into exposure (9), this was the rationale for choosing the 2 h 
time frame.
Data suggest increased risk to develop fatal pulmonary embo-
lism even after a 3-h duration of air travel (8). A recent case report 
describes bilateral pulmonary embolism after a short-haul flight 
in a man with multiple risk factors (29). In a hypobaric hypoxia 
study involving 20 healthy male volunteers, the authors showed 
TABLE 5 | Results from the control day.
Normal day
Controls Type 2 diabetes (T2DM)
Before After p CI/z (N) Before After p CI/z (N)
Lag time 436.11 ± 31.19 406.11 ± 45.50 0.04* −95.23 to 61.41 466.50 ± 76.64 422.70 ± 78.36 0.02* 9.28 to 78.32
Maximum 
absorption
0.404 ± 0.068 0.413 ± 0.064 0.12 1.20 to 58.80 0.340 ± 0.082 0.374 ± 0.109 0.31 −0.03 to 0.08
Lysis time 1628.33  
(1284.83, 2100.50)
1632.33  
(1305.25, 2488.25)
0.11 −1.60 (2) 1432.33  
(1325.25, 1578.67)
1427.83  
(1393.50, 1733.00)
0.20 −1.27 (4)
Lysis area 732.77  
(434.31, 1250.34)
772.05  
(427.26, 1227.70)
0.09 −1.72 (1) 607.38  
(496.64, 683.83)
635.65  
(537.14, 680.33)
0.33 −0.97 (3)
Clotting indices in healthy volunteers and participants with T2DM during the control experiment. There was decrease in lag time in both groups.
TABLE 4 | Platelet sensitivity to PGI2 prior to and after the relative hypoxia of the simulated flight (SF) intervention showing no difference in deactivation of the ADP 
activated platelets between controls and patients with type 2 diabetes (T2DM).
Fibrinogen binding
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
PGI2 1 nM ± ADP 42.40 ± 15.58 37.37 ± 17.85 0.08 −0.72 to 10.77 36.22 ± 8.83 35.07 ± 19.28 0.89 −18.08 to 20.38
PGI2 10 nM ± ADP 56.72 ± 15.73 54.62 ± 14.08 0.55 −5.57 to 9.78 51.40 ± 11.06 49.10 ± 19.36 0.78 −16.39 to 20.97
PGI2 100 nM ± ADP 95.98 (86.68, 97.09) 94.19 (91.06, 95.62) 0.88 −0.15 (6) 92.41 (83.82, 96.49) 95.45 (93.69, 96.25) 0.26 −1.13 (3)
P-selectin expression
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
PGI2 1 nM ± ADP 41.71 ± 15.98 40.25 ± 18.35 0.54 −3.66 to 6.57 33.88 ± 9.15 36.42 ± 7.97 0.55 −11.97 to 6.89
PGI2 10 nM ± ADP 50.90 (49.31, 57.06) 57.85 (39.63, 70.93) 0.96 −0.05 (4) 49.52 (33.42, 53.04) 53.73 (40.88, 55.12) 0.59 −0.53 (4)
PGI2 100 nM ± ADP 91.99 (84.57, 94.79) 92.82 (86.96, 95.84) 0.66 −0.96 (6) 86.53 (78.21, 91.43) 89.15 (84.64, 92.57) 0.59 −0.53 (4)
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that prothrombin 1 and 2 fragment levels reached maximum 
levels at 2 h into exposure (9). These data justify the short dura-
tion of our study visits in the absence of relevant data involving 
patients with T2DM.
There was increased maximum clot absorption following 
the SF indicating denser clot structure for both normal and 
participants with T2DM. This suggests that some elements 
of the clotting mechanism with greater clot density may be 
affected both in healthy participants and participants with 
T2DM equally. This suggests that should a thrombus form, 
its dissolution may be more difficult and prolonged (13). 
Conversely the lag (clotting time) and the lysis time here did 
not differ between normal and diabetes before or after the SF 
suggesting that enhanced clot formation would seem unlikely 
to occur and is reassuring that is not an enhanced risk for 
VTE. Lag time decreased in both groups during the control 
day, which may represent a circadian rhythm (30). To account 
for any circadian changes, participants entered and exited the 
environmental chamber at the same time during the different 
visits. This is superficially discrepant to a report detailing that 
there were no differences in soluble coagulation factors follow-
ing a hypoxic SF, but the detailed clotting parameters in that 
study were not performed (31).
Fibrinogen binding and P-selectin expression on platelets 
were increased in T2DM participants, but not controls, after 
the hypoxia of the SF indicating platelet hyperactivity. However, 
the incremental degree of platelet activation with ADP was not 
enhanced and did not differ between normal and participants 
with T2DM. Furthermore, inactivation of the ADP activated 
platelets by PGI2 was not altered between groups or after the 
SF. This suggests that the SF increased and perhaps would prime 
platelet activation, but once activated then the response would 
not differ to normal, and platelet inactivation mechanisms were 
also unaffected. These findings are in accord with data show-
ing that T2DM is associated with altered platelet function and 
metabolism (32). These data differ to the report of plasma soluble 
p-selectin and beta-thromboglobulin being unchanged following 
8 h SF; however, those serum markers are relatively insensitive to 
platelet changes (31). These data suggest that whilst basal platelet 
function may be affected by diabetes that there was no enhanced 
functional changes due to aircraft environmental conditions as 
shown by ADP or PGI2 being unaffected.
There was an increase in baseline endothelial MPs in T2DM 
in comparison to control that was expected as a measure of EC 
dysfunction (33), but MPs and the RHI were unaffected by the SF 
indicating no further deterioration of endothelial function.
TABLE 6 | Results from the control day.
Fibrinogen binding
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
Basal 2.38 (1.89, 2.86) 2.08 (1.85, 2.33) 0.24 −1.17 (7) 2.48 (2.34, 3.08) 2.25 (2.08, 2.66) 0.61 −0.51 (5)
ADP 0.1 µm 4.55 (3.63, 7.00) 3.90 (3.01, 5.86) 0.51 −0.66 (6) 7.30 (2.74, 12.15) 5.50 (3.41, 8.26) 0.14 −1.48 (6)
ADP 1 µm 42.92 ± 9.96 44.99 ± 11.32 0.32 −6.49 to 2.35 48.49 ± 18.10 45.70 ± 18.13 0.14 −1.06 to 6.64
ADP 10 µm 64.12 ± 12.80 63.13 ± 11.16 0.65 −3.80 to 5.77 66.53 ± 17.89 64.61 ± 17.26 0.39 −2.86 to 6.70
P-selectin expression
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
Basal 1.70 (1.54, 4.03) 1.60 (1.53, 2.54) 0.21 −1.25 (6) 2.10 (1.70, 2.43) 1.85 (1.60, 2.18) 0.48 −0.71 (6)
ADP 0.1 µm 4.20 (2.94, 6.71) 3.43 (2.90, 6.20) 0.96 −0.05 (5) 4.98 (3.25, 10.06) 4.48 (3.75, 7.15) 0.39 −0.87 (5)
ADP 1 µm 40.37 ± 11.94 43.86 ± 11.69 0.12 −8.14 to 1.16 42.92 ± 17.36 41.81 ± 14.72 0.52 −2.63 to 4.85
ADP 10 µm 62.93 ± 14.73 63.71 ± 12.46 0.75 −6.05 to 4.50 62.59 ± 18.08 62.95 ± 14.48 0.85 −4.60 to 3.89
Fibrinogen binding
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
PGI2 1 nM ± ADP 44.00 ± 11.38 40.33 ± 11.07 0.28 −3.57 to 10.91 40.03 ± 15.47 43.96 ± 19.73 0.51 −16.89 to 9.02
PGI2 10 nM ± ADP 58.27 ± 16.65 57.55 ± 12.37 0.92 −15.07 to 16.50 50.51 ± 18.68 53.98 ± 17.50 0.37 −11.83 to 4.89
PGI2 100 nM ± ADP 93.69  
(83.17, 96.36)
94.50  
(87.02, 96.86)
0.96 −0.05 (5) 93.61  
(82.93, 95.20)
91.75  
(84.79, 95.38)
0.39 −0.87 (3)
P-selectin expression
Controls T2DM
Before After p CI/z (N) Before After p CI/z (N)
PGI2 1 nM ± ADP 44.98 ± 8.97 42.35 ± 10.84 0.43 4.58 to 9.48 43.47 ± 14.91 43.96 ± 19.73 0.51 −17.82 to 9.46
PGI2 10 nM ± ADP 60.35 ± 16.21 58.22 ± 14.62 0.78 −14.26 to 18.51 54.02 ± 16.46 56.70 ± 13.23 0.38 −9.28 to 3.92
PGI2 100 nM ± ADP 93.98  
(83.17, 96.36)
92.93  
(85.83, 96.95)
0.96 −0.05 (5) 93.91  
(85.80, 95.27)
91.86  
(87.79, 96.00)
0.58 −0.56 (4)
Platelet function in healthy volunteers and patients with T2DM during the control experiment.
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Interestingly, there was a significant decrease in lag time in 
both healthy controls and patient with T2DM during the control 
day while there was no change during the hypoxic experiment and 
this may related to circadian changes (30). When comparing the% 
changes during the normoxic and hypoxic experiments, there was 
no significant difference. These with our other data are in line 
with a previously published cross-over study where increase in 
the thrombin–antithrombin complex was reported following an 
8-h flight compared to an 8-h movie marathon or 8 h of normal 
daily activity where greater changes were observed in participants 
who had Factor V Leiden mutation or were taking OCPs (34). In 
a different study, 20 participants of whom 10 had risk factors to 
develop VTE took part in a long-haul flight. There was increased 
activity of FVII and FVIII with suppressed fibrinolysis though 
there was no difference between the two groups (35).
A meta-analysis reported that there was a 1.4-fold increased 
risk to develop VTE in participants with diabetes (36). However, 
the data reported here are in accord with others suggesting that a 
SF would not cause an elevated VTE risk in T2DM (31).
The main limitation of this study is the small number 
of participants for both those with T2DM and the healthy 
controls. The random order of the environmental exposure 
circumvented any bias in the results that may have been due to 
only one exposure followed by the other. The cross over design 
was preferred as each participant could as their own control, 
particularly as it was unclear if normoxia (control) would 
have specific individual effects by itself. Gender distribution 
between the groups may have influenced the results; however, 
given the limited differences seen between the normal con-
trols and T2DM in this study, it would suggest that short haul 
commercial flying poses no additional hazards for those with 
T2DM.
In conclusion, there was increased clot density following a 
hypoxic SF, but dynamic tests of clotting, platelet function, and 
endothelial function did not differ suggesting that short haul 
commercial flying adds no additional hazard for VTE in T2DM 
compared to normal healthy control participants.
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